A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.

MicroCloud Hologram Inc. (NASDAQ: HOLO), (HOLO or the Company), a technology service provider, has launched a groundbreaking ...

Biologists have used machine learning, a type of AI, to identify 'synthetic extreme' DNA sequences with specifically designed functions in gene activation. They tested 50 million DNA sequences and ...